Toxicology studies often put a brake on the progression of health authority applications for FIH. To counter this challenge, Lonza’s new accelerated tox offering for mAbs can generate toxicology material within 10 weeks post-transfection. This enables our customers to initiate toxicology studies two months or more sooner and minimizes potential delays to regulatory application.
“We are also developing accelerated tox delivery processes for high concentration mAb formulations and more complex molecular formats,” says James Berrie, Technical Director, Global Process Development. Find out more in this Labiotech interview article featuring insights from my colleagues Alejandro Fernandez Martell, Global Principal Scientist and James Berrie.
–> Contact your dedicated Business Development Specialist, Amanda Holmsten, at amanda.holmsten@lonza.com if you wish to discuss further with Lonza’s experts.